HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
about
HER2 testing: a review of detection methodologies and their clinical performanceHER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewPredictive factors for response to docetaxel in human breast cancers.Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern IndiaRecent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
P2860
Q28280488-39CD0551-3081-4EE8-A895-640FD34B7A9FQ33275622-3FE5034D-964B-400B-A5C2-CE06B074F722Q34048144-CA97F92D-4CF5-4A14-9BF7-0529C3E1F00AQ34328227-C3556D8D-8B5C-4041-BCF8-63DEF9092D8AQ34863131-DB632D49-B784-4630-B9BA-59980A858E77Q35145309-15A80AF2-6148-4F99-9F87-4256FB32B93BQ35904441-6A7E3992-232D-4FA3-BEED-5A2FD7F48B02Q36521963-D069D59D-91B4-4B2C-8C5D-70A47A20DE76Q36634397-B22E31EA-4F54-4ABE-95CF-E0BCEB5203B3Q37208757-2F9245B7-FE07-4D5D-9F25-655F7289B3E1Q37641078-1026CAD3-49F3-4B38-9A1C-A338AE75103AQ41722410-249698D4-06B7-49EE-A646-B0553A5C34E3Q42486311-9E235C87-2C5B-4170-81FE-5A4FB840345D
P2860
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@ast
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@en
type
label
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@ast
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@en
prefLabel
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@ast
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@en
P2093
P356
P1433
P1476
HER-2/neu expression as a pred ...... ith operable breast carcinoma.
@en
P2093
Anatolio B Cruz
Brad H Pollock
Dennis L Rousseau
Frances E Sharkey
Gary B Chisholm
I-Tien Yeh
Michelle McNutt
Morton S Kahlenberg
Peter A Learn
P304
P356
10.1002/CNCR.21037
P407
P577
2005-06-01T00:00:00Z